A detailed history of Axa S.A. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Axa S.A. holds 53,513 shares of BGNE stock, worth $10.1 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
53,513
Previous 53,498 0.03%
Holding current value
$10.1 Million
Previous $7.63 Million 57.42%
% of portfolio
0.04%
Previous 0.02%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$143.93 - $224.51 $2,158 - $3,367
15 Added 0.03%
53,513 $12 Million
Q2 2024

Aug 14, 2024

BUY
$129.52 - $174.32 $4,015 - $5,403
31 Added 0.06%
53,498 $7.63 Million
Q1 2024

May 15, 2024

SELL
$141.8 - $181.47 $236,380 - $302,510
-1,667 Reduced 3.02%
53,467 $8.36 Million
Q4 2023

Jul 16, 2024

BUY
$158.67 - $201.58 $264,502 - $336,033
1,667 Added 3.12%
55,134 $9.94 Million
Q4 2023

Feb 14, 2024

SELL
$158.67 - $201.58 $204,842 - $260,239
-1,291 Reduced 2.29%
55,134 $9.94 Million
Q3 2023

Nov 14, 2023

SELL
$179.87 - $225.13 $34,714 - $43,450
-193 Reduced 0.34%
56,425 $10.1 Million
Q2 2023

Aug 14, 2023

BUY
$178.3 - $266.78 $6.44 Million - $9.64 Million
36,139 Added 176.47%
56,618 $10.1 Million
Q1 2023

May 15, 2023

BUY
$215.53 - $274.5 $3.26 Million - $4.15 Million
15,120 Added 282.14%
20,479 $4.41 Million
Q4 2022

Feb 14, 2023

SELL
$125.51 - $229.3 $2.93 Million - $5.35 Million
-23,337 Reduced 81.32%
5,359 $1.18 Million
Q3 2022

Feb 14, 2023

BUY
$131.8 - $202.24 $24,119 - $37,009
183 Added 0.64%
28,696 $3.87 Million
Q3 2022

Nov 14, 2022

BUY
$131.8 - $202.24 $24,119 - $37,009
183 Added 0.64%
28,696 $3.87 Million
Q2 2022

Feb 14, 2023

SELL
$121.11 - $216.05 $66,973 - $119,475
-553 Reduced 1.9%
28,513 $4.61 Million
Q2 2022

Aug 15, 2022

SELL
$121.11 - $216.05 $66,973 - $119,475
-553 Reduced 1.9%
28,513 $4.62 Million
Q1 2022

Feb 14, 2023

BUY
$146.52 - $269.56 $54,212 - $99,737
370 Added 1.29%
29,066 $5.48 Million
Q1 2022

May 13, 2022

BUY
$146.52 - $269.56 $43,662 - $80,328
298 Added 1.04%
29,066 $5.48 Million
Q4 2021

Feb 14, 2022

BUY
$248.56 - $389.34 $85,504 - $133,932
344 Added 1.21%
28,768 $7.79 Million
Q3 2021

Nov 15, 2021

SELL
$249.6 - $403.14 $3.31 Million - $5.35 Million
-13,266 Reduced 31.82%
28,424 $10.3 Million
Q2 2021

Aug 13, 2021

SELL
$292.75 - $367.01 $1.46 Million - $1.82 Million
-4,972 Reduced 10.66%
41,690 $14.3 Million
Q1 2021

May 14, 2021

BUY
$260.64 - $382.12 $28,409 - $41,651
109 Added 0.23%
46,662 $16.2 Million
Q4 2020

Feb 12, 2021

BUY
$221.31 - $316.61 $3.53 Million - $5.05 Million
15,955 Added 52.14%
46,553 $12 Million
Q3 2020

Nov 13, 2020

BUY
$189.18 - $286.44 $521,758 - $790,001
2,758 Added 9.91%
30,598 $8.76 Million
Q2 2020

Aug 14, 2020

BUY
$123.9 - $195.41 $160,078 - $252,469
1,292 Added 4.87%
27,840 $5.25 Million
Q1 2020

May 15, 2020

SELL
$121.84 - $173.19 $249,406 - $354,519
-2,047 Reduced 7.16%
26,548 $3.27 Million
Q4 2019

Feb 18, 2020

BUY
$115.78 - $208.34 $83,130 - $149,588
718 Added 2.58%
28,595 $4.74 Million
Q3 2019

Nov 14, 2019

SELL
$120.61 - $148.29 $4.92 Million - $6.05 Million
-40,769 Reduced 59.39%
27,877 $3.41 Million
Q2 2019

Aug 13, 2019

BUY
$113.99 - $146.86 $157,648 - $203,107
1,383 Added 2.06%
68,646 $8.51 Million
Q1 2019

May 14, 2019

BUY
$122.82 - $151.83 $8.26 Million - $10.2 Million
67,263 New
67,263 $8.88 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $19.6B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Axa S.A. Portfolio

Follow Axa S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.